Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Transforming Growth Factor (TGF), particularly TGF-beta, has been investigated for its potential role in reducing certain side effects of chemotherapy, especially chemotherapy-induced mucositis (painful inflammation and ulceration of the mucous membranes lining the digestive tract). Scientific studies, mainly in the form of clinical trials and animal studies, have shown that TGF-beta can promote the repair and regeneration of epithelial tissues. For example, several randomized controlled trials in cancer patients (especially those undergoing bone marrow transplantation or aggressive chemotherapy) have tested recombinant human TGF-beta or TGF-beta-rich enteral formulas. These studies demonstrate that TGF-beta may reduce the severity and duration of oral and gastrointestinal mucositis, thereby improving patient comfort and potentially allowing better adherence to chemotherapy regimens.

However, the evidence is moderate (rated 3/5), as large-scale, definitive clinical trials are limited and TGF-beta is not universally adopted as a standard supportive care agent. There are also concerns about the potential for TGF-beta to promote tumor growth or fibrosis in some contexts, which limits its widespread application. Overall, there is scientific validation, especially for mucosal protection, but recommendations for routine use are still cautious and context-dependent.

More about Transforming growth factor
More about Chemotherapy (reducing side effects)

Other ingredients used for Chemotherapy (reducing side effects)

Other health conditions supported by Transforming growth factor

Products containing Transforming growth factor